The National Science Foundation (NSF) awarded a $275,000 SBIR Phase I grant to Synsorybio, Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The goal of this project is to develop a method to activate cancer immunotherapies only at the site of disease, in order to create safer and more effective cancer treatments. The project aims to engineer protein-based therapeutics that can "sense and respond" to disease signals, turning on the immunotherapy only where it is needed and avoiding off-target effects in healthy tissues. This proof-of-concept project may lay the groundwork for a versatile platform technology to conditionally control the activity of protein-based drugs, with potential applications across various therapeutic areas. The award period runs from July 2024 to February 2025.
Generated 2/25/25, 3:30 AM